BioSyent Inc. 的盈利质量评分为 /。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
BioSyent Inc. 何时发布财报?
BioSyent Inc. 的下一份财报预计在 2026-08-12 发布
BioSyent Inc. 的预期收益是多少?
根据华尔街分析师的预测,BioSyent Inc. 的预期收益为 $
BioSyent Inc. 是否超出收益预期?
BioSyent Inc. 最近的收益为 $, 预期。
关键数据
前收盘价
$9.88
开盘价
$9.86
当日区间
$9.85 - $9.9
52周范围
-
交易量
--
平均成交量
--
股息收益率
--
每股收益(TTM)
--
市值
--
什么是 BioSyent Inc.?
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., and Hedley Technologies (USA) Inc., a wholly owned subsidiary, operates the Company’s business marketing biologically and health-friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn and Tibella, among others. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 is for the treatment of iron deficiency anemia. The firm also provides specialized healthcare products for dental hygiene and oral health.